Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfectionFloriane Gallais, Samira Fafi‐Kremer, Baptiste Panaget et al.|EBioMedicine|2021Cited by 239
Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasionDelphine Planas, Olivier Schwartz|Nature Communications|2024Cited by 237
Repurposing Metformin in Nondiabetic People With HIV: Influence on Weight and Gut MicrobiotaStéphane Isnard, Jean‐Pierre Routy, John Lin et al.|Open Forum Infectious Diseases|2020Cited by 49
Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasionDelphine Planas, Olivier Schwartz|bioRxiv (Cold Spring Harbor Laboratory)|2023Cited by 40
Sotrovimab therapy elicits antiviral activities against Omicron BQ.1.1 and XBB.1.5 in sera of immunocompromised patientsTimothée Bruel, Claire Delage, Lou-Léna Vrignaud et al.|Med|2023Cited by 16